Bibliographic Details
Title: |
A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer. |
Authors: |
Girda, Eugenia1 (AUTHOR), Makker, Vicky2 (AUTHOR), Marth, Christian3 (AUTHOR), Van Gorp, Toon4 (AUTHOR), Mirza, Mansoor5 (AUTHOR), Shapira-Frommer, Ronnie6 (AUTHOR), Suttner, Leah7 (AUTHOR), Groisberg, Roman7 (AUTHOR), Jin, Fan7 (AUTHOR), O'Malley, David8 (AUTHOR) |
Source: |
Gynecologic Oncology. 2024 Supplement 1, Vol. 190, pS293-S294. 2p. |
Subject Terms: |
*ENDOMETRIAL cancer, *PEMBROLIZUMAB |
Database: |
Academic Search Complete |